These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26868696)

  • 21. Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein).
    Samson RH; Nair DG
    Semin Vasc Surg; 2011 Sep; 24(3):172-9. PubMed ID: 22153029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRP in cardiovascular disease.
    Karakas M; Koenig W
    Herz; 2009 Dec; 34(8):607-13. PubMed ID: 20024640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
    Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
    Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventive cardiology: move over low density lipoprotein cholesterol, hello C-reactive protein?
    Genest J
    Can J Cardiol; 2004 Aug; 20 Suppl B():89B-92B. PubMed ID: 15309211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The JUPITER trial: How will it change clinical practice?
    Watson KE
    Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
    Pfützner A; Forst T
    Diabetes Technol Ther; 2006 Feb; 8(1):28-36. PubMed ID: 16472048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Markers of inflammation and cardiovascular disease: clinical applications of C-reactive protein determination.
    Martínez VB; González-Juanatey JR
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():3-7. PubMed ID: 20000881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Another look at the results of the JUPITER trial.
    Kappagoda CT; Amsterdam EA
    Am J Cardiol; 2009 Dec; 104(11):1603-5. PubMed ID: 19932800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The JUPITER study: background and research hypotheses].
    Rapezzi C; Gallo P
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):25S-27S. PubMed ID: 21298858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [High sensitivity of C-reactive protein in primary prevention].
    Corrado E; Novo S
    G Ital Cardiol (Rome); 2007 Jun; 8(6):327-34. PubMed ID: 17633905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective.
    Kamath DY; Xavier D; Sigamani A; Pais P
    Indian J Med Res; 2015 Sep; 142(3):261-8. PubMed ID: 26458341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
    de Ferranti SD; Rifai N
    Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
    Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores.
    Ridker PM; Cook N
    Circulation; 2004 Apr; 109(16):1955-9. PubMed ID: 15051634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Association between baseline high sensitivity C-reactive protein level and the first cardio-cerebral vascular event in diabetic population: a prospective cohort study].
    Wang LY; Wu SL; Yang XL; Wang TJ; Su LR; Gao JS; Zheng XM; Liu XR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):749-54. PubMed ID: 22169424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.